Molecular Pharmacology

G Protein Coupled Receptor Allosteric Modulation

Investigation of allosteric binding sites on GPCRs to develop selective modulators with reduced side effects compared to orthosteric ligands.

RESEARCH GAP FRONTIERS

Kinase Inhibitor Selectivity and Off Target Effects

Study of kinase inhibitor specificity across the human kinome to predict and minimize unintended pharmacological interactions.

RESEARCH GAP FRONTIERS

Epigenetic Drug Target Discovery and Validation

Identification and characterization of histone deacetylases, methyltransferases, and other epigenetic enzymes as therapeutic targets for cancer and neurological diseases.

RESEARCH GAP FRONTIERS

Proteolysis Targeting Chimeras Rational Design

Development of PROTAC molecules that recruit E3 ligases to degrade undruggable protein targets through the proteasomal pathway.

RESEARCH GAP FRONTIERS

Ion Channel Pharmacology and Patch Clamp Studies

Electrophysiological characterization of drug interactions with voltage and ligand gated ion channels at single channel resolution.

RESEARCH GAP FRONTIERS

Nuclear Receptor Ligand Binding Domain Interactions

Structural and functional analysis of selective estrogen and androgen receptor modulators with tissue specific pharmacology.

RESEARCH GAP FRONTIERS

Drug Transporter Mediated Resistance Mechanisms

Investigation of ATP binding cassette and solute carrier transporter upregulation in cancer cell drug resistance and bioavailability optimization.

RESEARCH GAP FRONTIERS

Metabolic Enzyme Inhibition and Drug Drug Interactions

Characterization of cytochrome P450 and other metabolic enzyme inhibition patterns to predict clinically relevant drug drug interactions.

Phenotypic Screening for Novel Mechanism Discovery

High throughput phenotypic assays in disease models to identify compounds with novel mechanisms prior to target identification.

Protein Folding and Aggregation Pharmacology

Development of molecular chaperone modulators and aggregation inhibitors for treating neurodegenerative diseases caused by protein misfolding.

Immunopharmacology and Checkpoint Inhibitor Development

Design of monoclonal antibodies and small molecules targeting PD 1, PD L1, and CTLA 4 pathways in cancer immunotherapy.

Ligand Induced Protein Degradation via PROTAC

Optimization of protein target and E3 ligase recruitment strategies for efficient degradation of disease associated proteins.

Structure Based Drug Design and Computational Docking

Utilization of X ray crystallography and cryo EM structures to computationally design high affinity and selective ligands.

Biomarker Development for Pharmacogenomic Prediction

Identification of genetic and proteomic biomarkers predicting patient response and adverse drug reactions for precision medicine.

Nicotinic Receptor Modulation in Neurological Disease

Development of subtype selective nicotinic receptor agonists and antagonists for Alzheimer''s disease and cognitive dysfunction treatment.

Voltage Gated Sodium Channel Pharmacology

Characterization of state dependent sodium channel blockers for pain management and cardiac arrhythmia treatment.

CRISPR Pooled Screening for Drug Target Identification

Genome wide functional screens using CRISPR Cas9 to identify genetic modulators of compound efficacy and toxicity.

Membrane Protein Conformational Dynamics

Investigation of ligand induced conformational changes in membrane proteins using molecular dynamics simulations and spectroscopy.

Orally Bioavailable Natural Product Optimization

Chemical modification of natural product scaffolds to enhance stability, permeability, and oral bioavailability while maintaining potency.

Blood Brain Barrier Permeability Prediction Models

Development of in vitro BBB models and computational algorithms to predict central nervous system drug penetration.

Enzyme Kinetics and Mechanism of Inhibition

Quantitative analysis of competitive, non competitive, and irreversible enzyme inhibition mechanisms using steady state and pre steady state kinetics.

Biased Signaling and Beta Arrestin Pathway Activation

Discovery of ligands biased toward specific downstream signaling cascades to improve therapeutic efficacy and reduce adverse effects.

Chemogenetic Tool Development for Pharmacology

Engineering of receptors with non canonical ligand binding properties for selective pharmacological control of engineered proteins.

Photopharmacology and Light Activated Drugs

Design of azobenzene and diarylethene based molecules with spatiotemporal control over target engagement.

Organotypic Tissue Model Drug Response Profiling

Evaluation of drug efficacy and toxicity using 3D organ on chip and tissue engineering platforms mimicking in vivo physiology.

Transient Receptor Potential Channel Modulation

Development of selective TRP channel antagonists and agonists for pain, temperature sensation, and metabolic disorder treatment.

Protein Protein Interaction Modulators Discovery

Rational design of small molecules and peptides disrupting disease associated protein protein interaction interfaces.

Cytochrome P450 Induction and Gene Regulation

Investigation of nuclear receptor mediated transcriptional upregulation of CYP enzymes affecting drug drug interaction potential.

Target Engagement Assessment in Living Systems

Real time measurement of target occupancy in cells and tissues using thermal shift assays and fluorescence recovery.

Antimicrobial Peptide Design and Optimization

Structure activity relationship optimization of host defense peptides with reduced toxicity and enhanced antimicrobial activity.

Machine Learning Models for Drug Potency Prediction

Development of artificial intelligence algorithms integrating molecular descriptors and bioactivity data for compound ranking.

Cardiovascular Drug Safety and QT Prolongation

Characterization of hERG channel blockade and cardiac action potential effects predicting torsades de pointes liability.

Serotonin Receptor Subtype Selective Ligands

Design of selective 5 HT receptor agonists and antagonists targeting specific receptor subtypes for psychiatric disease.

Neddylation Pathway Inhibition and Mechanism

Investigation of NEDD8 conjugation inhibitors and their effects on Cullin RING ligase activity and protein stability.

Single Cell Pharmacodynamics and Heterogeneity

Analysis of drug induced pathway activation and cell state changes in heterogeneous cell populations using single cell sequencing.

Wnt Signaling Pathway Modulators and Antagonists

Development of porcupine and tankyrase inhibitors modulating Wnt beta catenin signaling in cancer and regenerative medicine.

Hepatic Stellate Cell Activation Inhibition

Discovery of compounds blocking hepatic stellate cell activation and transdifferentiation to prevent liver fibrosis progression.

Target Deconvolution from Phenotypic Screening Hits

Unbiased identification of molecular targets from active compounds using affinity chromatography and chemical proteomics.

Lipid Raft Disruption and Membrane Organization

Investigation of drug effects on lipid raft organization and its consequences for receptor signaling and trafficking.

Autophagy Modulation for Lysosomal Storage Disease

Development of mTOR inhibitors and autophagy enhancers promoting clearance of accumulated substrates in lysosomal disorders.

DNA Damage Response Pathway Pharmacology

Design of PARP inhibitors, ATM kinase inhibitors, and checkpoint kinase modulators for cancer therapy potentiation.

Metabolite Identification and Reactive Intermediate Detection

Mass spectrometry based characterization of drug metabolites and detection of reactive metabolite formation for toxicity prediction.

Hedgehog Signaling Inhibition in Cancer

Development of smoothened antagonists and GLI protein inhibitors for medulloblastoma and basal cell carcinoma treatment.

Fluorescent Probe Design for Target Validation

Creation of fluorescently labeled pharmacophores for real time visualization of target localization and binding dynamics.

Notch Signaling Modulation in Development

Investigation of gamma secretase inhibitors and Notch receptor activators for cancer and degenerative disease treatment.

Mitochondrial Bioenergetics and Drug Effects

Assessment of drug induced mitochondrial dysfunction through oxygen consumption rates and membrane potential measurements.

Formulation Technology for Poorly Soluble Compounds

Development of lipid based formulations, nanoparticles, and amorphous solid dispersions enhancing bioavailability of hydrophobic drugs.

Opioid Receptor Biased Agonism and Analgesia

Design of mu opioid receptor agonists biased toward G protein signaling to maximize pain relief while minimizing respiratory depression.

Toll Like Receptor Agonists Immunotherapy

Development of TLR 7, TLR 8, and TLR 9 agonists enhancing innate immune responses for cancer immunotherapy.

Plant Phenolic Compound Absorption and Metabolism

Characterization of bioavailability and metabolic fate of flavonoids and phenolic acids in intestinal absorption models.

Allosteric Modulation of Nuclear Hormone Receptors

Investigation of allosteric binding sites on nuclear receptors to develop tissue-selective agonists and antagonists with improved therapeutic windows.

Covalent Inhibitor Design and Reactivity Kinetics

Rational design of irreversible covalent inhibitors targeting nucleophilic residues in drug targets with optimization of reaction kinetics and selectivity.

Scaffold Hopping for Target Selectivity Enhancement

Strategic replacement of core chemical scaffolds to improve selectivity profiles and reduce off-target liabilities while maintaining binding affinity.

Deuterium Isotope Effects on Drug Metabolism

Utilization of deuterated compounds to slow metabolic degradation and improve pharmacokinetic properties through selective C-H bond stabilization.

Fragment Based Drug Discovery and Linking

Development of lead compounds through systematic combination of low-molecular-weight fragments with high ligand efficiency identified via structural biology.

Thermal Shift Assays for Binding Affinity

Quantification of ligand binding through target protein stabilization measured by differential scanning fluorimetry and thermal denaturation kinetics.

RNA Aptamer Drug Development and Optimization

Selection and engineering of nucleic acid aptamers as therapeutic agents with improved cellular uptake and resistance to nuclease degradation.

Prodrug Activation and Bioconversion Pathways

Design of inactive prodrugs activated by specific metabolic enzymes or disease-associated proteases to achieve tissue-selective drug release.

Cytokine Receptor Signaling Inhibition

Development of JAK-STAT pathway inhibitors targeting interleukin and interferon receptors for inflammatory and neoplastic disease treatment.

Surface Plasmon Resonance Kinetic Profiling

Real-time measurement of drug-target binding kinetics including association and dissociation rates to predict in vivo drug efficacy.

Phosphodiesterase Isoform Selective Inhibition

Rational design of PDE inhibitors with selectivity for specific isoforms to modulate cyclic nucleotide signaling in disease-relevant tissues.

Metabolic Syndrome Drug Target Validation

Identification and pharmacological validation of targets involved in glucose metabolism, lipid homeostasis, and insulin sensitivity.

Solubility Enhancement via Salt Formation

Strategic selection of organic and inorganic counterions to improve aqueous solubility and oral bioavailability of poorly soluble drugs.

Three Dimensional Quantitative Structure Activity Relationships

Application of 3D molecular field analysis and pharmacophore modeling to predict binding affinity based on steric and electrostatic properties.

Ubiquitin Proteasome System Drug Targets

Development of E1 and E3 ligase inhibitors to modulate protein degradation for cancer and neurodegenerative disease therapy.

Purinergic Receptor P2Y Antagonism

Design of selective P2Y receptor antagonists to inhibit nucleotide-mediated signaling in thrombosis and inflammatory diseases.

Osteoclast Differentiation Factor Inhibition

Pharmacological modulation of RANKL signaling and osteoclastogenic pathways for osteoporosis and bone metastasis treatment.

Fluorescence Recovery After Photobleaching Dynamics

Measurement of drug-induced alterations in protein diffusion and mobility within cellular compartments using FRAP microscopy techniques.

Glycogen Synthase Kinase Three Beta Inhibition

Development of GSK3β inhibitors for modulation of Wnt and other signaling pathways in neuropsychiatric and oncologic applications.

Lipopolysaccharide Receptor TLR4 Antagonism

Rational design of TLR4 antagonists to suppress endotoxin-mediated inflammatory responses in sepsis and autoimmune conditions.

Time Resolved Fluorescence Resonance Energy Transfer

Application of TR-FRET technology to quantify drug-induced protein interactions and conformational changes in live cells.

Fibroblast Growth Factor Receptor Inhibition

Design of selective FGFR inhibitors with isoform specificity to target FGFR-driven cancers and fibrotic diseases.

Angiogenesis Inhibition and Vascular Targeting

Development of VEGF receptor and other angiogenic pathway inhibitors for tumor neovascularization suppression.

Sirtuin Activators and NAD Plus Metabolism

Pharmacological modulation of NAD-dependent sirtuins to promote cellular stress resistance and metabolic homeostasis.

Mitogen Activated Protein Kinase Cascade Inhibition

Development of selective MAPK pathway inhibitors targeting ERK, p38, and JNK signaling in cancer and inflammation.

Protein Tyrosine Phosphatase Inhibition Selectivity

Rational design of PTP inhibitors with selectivity for specific phosphatase isoforms to modulate receptor tyrosine kinase signaling.

Melanocortin Receptor Agonism and Antagonism

Development of selective melanocortin receptor ligands for obesity management and inflammatory skin disease treatment.

Carbonic Anhydrase Inhibitor Design

Development of selective carbonic anhydrase inhibitors targeting specific isoforms for glaucoma, diuresis, and cancer therapy.

Human Ether A Go Go Related Gene Cardiotoxicity

Assessment and mitigation of hERG channel blockade-induced QT prolongation through structure-based design of safer compounds.

Phosphoinositide Three Kinase Isoform Selectivity

Design of PI3K isoform-selective inhibitors to differentially target cancer cells and immune cells while minimizing metabolic toxicity.

Aryl Hydrocarbon Receptor Ligand Development

Development of AhR agonists and antagonists to modulate xenobiotic metabolism and immune cell differentiation in disease states.

Solute Carrier Transporter Pharmacology

Characterization of drug interactions with SLC transporters to predict substrate-specific transport and transporter-mediated drug resistance.

Bradykinin Receptor Antagonism in Inflammation

Design of B1 and B2 bradykinin receptor antagonists to suppress kallikrein-kinin pathway-mediated inflammatory responses.

Glucokinase Activator Development

Rational design of glucokinase activators to enhance glucose sensing and insulin secretion for type two diabetes management.

Aminoacyl Transfer RNA Synthetase Inhibition

Development of aaRS inhibitors targeting bacterial or parasite-specific synthetases for antimicrobial and antiparasitic drug discovery.

Farnesoid X Receptor Agonist Design

Development of FXR agonists to modulate bile acid homeostasis and metabolic signaling for cholestatic and metabolic disease treatment.

Adenosine Receptor Selective Agonism

Design of A1, A2a, and A3 adenosine receptor-selective agonists to modulate purinergic signaling in inflammation and neurodegeneration.

Serine Threonine Kinase Inhibitor Potency

Optimization of inhibitors targeting PKA, PKC, and AKT serine-threonine kinases for signal transduction modulation.

Endothelin Receptor Antagonist Selectivity

Development of selective ETA and ETB endothelin receptor antagonists for pulmonary hypertension and renal disease treatment.

Histone Deacetylase Inhibitor Pan Selectivity

Design of pan and isoform-selective HDAC inhibitors to induce chromatin remodeling and transcriptional changes in cancer therapy.

Mammalian Target of Rapamycin Pathway Inhibition

Development of mTOR kinase inhibitors and allosteric modulators to suppress protein synthesis and promote autophagy.

Melanin Concentrating Hormone Receptor Antagonism

Design of MCH receptor antagonists to reduce appetite and promote weight loss through central nervous system signaling modulation.

Fosfodiesterase Inhibition and Inflammation

Development of selective phosphodiesterase inhibitors to elevate cAMP and cGMP for immune cell suppression and anti-inflammatory effects.

Vanilloid Receptor Agonism and Pain

Design of TRPV1 agonists and antagonists for nociceptive pain modulation and thermoregulation in chronic pain syndromes.

Formyl Peptide Receptor Ligand Development

Development of FPR agonists and antagonists to modulate neutrophil chemotaxis and antimicrobial immune responses.

Plasmin Kallikrein Inhibitor Design

Rational design of specific inhibitors targeting serine proteases in coagulation and inflammation for thrombotic disease treatment.

Corticotropin Releasing Factor Receptor Antagonism

Development of CRF receptor antagonists to suppress stress-induced HPA axis activation for anxiety and depression treatment.

Neuropeptide Y Receptor Selective Modulation

Design of NPY receptor-selective agonists and antagonists to modulate appetite, anxiety, and stress responses.

Estrogen Receptor Beta Selective Agonism

Development of ERβ-selective agonists to avoid ERα proliferative effects while achieving neuroprotection and anti-inflammatory benefits.

Lysine Specific Demethylase Inhibition

Design of LSD1 and other KDM inhibitors to prevent histone demethylation and promote cancer cell differentiation.

Heterotrimeric G Protein Effector Selectivity Mechanisms

Elucidation of molecular determinants governing differential activation of downstream effectors by Gα subunit variants and Gβγ dimers in cellular signaling.

Scaffolding Protein Interactions in Signal Transduction

Structure-function studies of multi-domain scaffolding proteins that organize kinase signaling complexes and mechanisms for pharmacological disruption of these assemblies.

Lysosomal Acidification and Drug Sequestration Pharmacology

Analysis of weak base drug accumulation in lysosomes and development of strategies to overcome sequestration-mediated resistance in cancer therapeutics.

RAS Family GTPase Mutation Selective Inhibitors

Design of covalent and non-covalent small molecules that selectively target oncogenic KRAS, NRAS, and HRAS variants while sparing wild-type protein.

Bromodomain and Histone Acetyl Reader Pharmacology

Discovery and optimization of bromodomain inhibitors targeting BET proteins and other acetyl-lysine readers to modulate transcriptional programs in disease.

Histone Deacetylase Isoform Selective Inhibition

Development of HDAC inhibitors with selectivity for specific isoforms to achieve therapeutic benefit while minimizing pan-HDAC toxicity in cancer and neurological disease.

Ubiquitin Chain Topology Recognition and Modulation

Rational design of molecules targeting specific ubiquitin linkage types and deubiquitinase substrates to modulate protein fate in cellular signaling networks.

Kinase Domain ATP Competitive vs Non Competitive Inhibition

Comparative pharmacology of ATP-competitive and allosteric kinase inhibitors to understand selectivity, potency, and resistance development mechanisms.

Angiotensin II Receptor AT1 Biased Signaling

Development of angiotensin receptor ligands that preferentially activate beta-arrestin pathways over G protein signaling to achieve cardioprotective effects.

Sphingosine 1 Phosphate Receptor Modulators

Design of S1P receptor functional agonists and antagonists with tissue-specific delivery to modulate lymphocyte trafficking and vascular integrity.

Purinergic P2 Receptor Subtype Selectivity

Characterization of selective antagonists for P2X and P2Y receptor subtypes to develop therapeutics targeting inflammation and neuronal dysfunction.

Neuropeptide Receptor Conformational State Stabilization

Rational design of neuropeptide analogs and allosteric modulators that stabilize distinct GPCR conformations to achieve pathway-specific therapeutic outcomes.

Glutamate Receptor Allosteric Site Pharmacology

Discovery of molecules targeting allosteric sites on NMDA, AMPA, and kainate receptors to achieve neuroprotection with reduced psychotomimetic side effects.

Interleukin Receptor Signaling Pathway Selectivity

Development of selective IL receptor agonists and antagonists that modulate JAK-STAT signaling independently of alternative pathway activation.

TNF Receptor Superfamily Agonism and Antagonism

Rational design of TNFR superfamily ligands and antagonists to modulate immune cell costimulation and apoptosis signaling in cancer and autoimmunity.

Fibroblast Growth Factor Receptor Kinase Selectivity

Development of FGFR-selective tyrosine kinase inhibitors that overcome resistance mutations while minimizing off-target effects on other receptor tyrosine kinases.

Vascular Endothelial Growth Factor Receptor Balanced Inhibition

Optimization of multi-targeted VEGFR inhibitors achieving angiostatic effects while maintaining acceptable cardiac safety and preventing hypertension.

Insulin Receptor Substrate Protein Signaling Modulation

Design of small molecules modulating IRS phosphorylation and adaptor protein binding to enhance insulin sensitivity and glucose homeostasis.

Mammalian Target of Rapamycin Complex Selective Inhibition

Development of second-generation mTOR inhibitors achieving selective mTORC1 or mTORC2 inhibition to improve therapeutic efficacy in cancer and metabolic disease.

AMP Activated Protein Kinase Direct Activators

Discovery and optimization of small molecule AMPK activators that directly bind the kinase to enhance cellular energy metabolism and mitochondrial function.

Focal Adhesion Kinase Inhibition in Cancer Progression

Development of FAK-selective inhibitors targeting tumor cell migration and invasion while modulating immune cell adhesion for combinatorial immunotherapy.

Transforming Growth Factor Beta Signaling Modulation

Rational design of ALK5 and ALK4 inhibitors achieving selective SMAD2/3 pathway inhibition while preserving non-SMAD TGF-beta signaling.

Src Family Kinase Isoform Specific Inhibition

Design of Src, Yes, and Lyn selective inhibitors exploiting subtle structural differences to achieve kinase-specific and cell-type specific therapeutic effects.

Cyclin Dependent Kinase Selectivity and Cell Cycle Arrest

Development of CDK inhibitors with selectivity for specific CDK-cyclin complexes to achieve defined cell cycle checkpoint inhibition in cancer therapy.

Glycogen Synthase Kinase 3 Substrate Selectivity

Characterization of GSK3 inhibitors and their effects on selective substrate phosphorylation in Wnt and insulin signaling pathways for therapeutic applications.

Mixed Lineage Kinase Pathway Selective Modulation

Design of MLK inhibitors achieving selective MAP kinase pathway modulation with applications in neuroinflammation and neurodegeneration.

Janus Kinase Selectivity and STAT Independence

Development of JAK inhibitors with selectivity for JAK1, JAK2, or JAK3 while characterizing non-canonical JAK signaling pathways and their inhibition.

p38 Mitogen Activated Protein Kinase Isoform Selectivity

Discovery of p38 MAPK subtype-selective inhibitors targeting distinct inflammatory and stress response pathways in immune and metabolic disorders.

Extracellular Signal Regulated Kinase Feedback Inhibition

Characterization of ERK inhibitors and their effects on negative feedback loops to prevent compensatory MAPK pathway activation in cancer cells.

Phosphoinositide 3 Kinase Isoform Selectivity Pharmacology

Design of PI3K p110 isoform-selective inhibitors achieving cell-type specific AKT pathway modulation with improved tolerability in cancer immunotherapy.

AKT Serine Threonine Kinase Allosteric Inhibition

Development of allosteric AKT inhibitors that preserve PIP3 binding and achieve selective isoform inhibition to overcome resistance mechanisms.

Phosphatidylinositol 4,5 Bisphosphate Signaling Modulation

Design of compounds targeting PIP2 hydrolysis and phosphatidylinositol kinases to modulate receptor signaling and cytoskeletal dynamics.

Phosphatase 2A Inhibition and Protein Phosphorylation

Selective inhibition of PP2A catalytic subunit variants to enhance therapeutic kinase inhibitor efficacy through sustained target phosphorylation.

Calcineurin Phosphatase Substrate Selectivity Modulation

Design of calcineurin inhibitors achieving selective NFAT dephosphorylation while preserving other calcineurin substrates for improved immunosuppression.

Protein Tyrosine Phosphatase Family Selective Inhibition

Discovery of inhibitors targeting specific PTP family members including PTPN22, PTPN6, and dual-specificity phosphatases for autoimmunity and cancer.

Calcium Calmodulin Dependent Kinase II Modulation

Rational design of CaMKII inhibitors achieving isoform selectivity and subcellular localization targeting for synaptic plasticity and cardiac rhythm modulation.

Phospholipase C Isoform Selectivity and Second Messenger Generation

Development of PLC inhibitors selective for specific isoforms to achieve differential modulation of IP3 and DAG signaling pathways.

Adenylyl Cyclase Activation and cAMP Signaling Modulation

Design of direct adenylyl cyclase activators and phosphodiesterase inhibitors achieving sustained cAMP elevation with cell-type selectivity.

Guanylate Cyclase Activation and cGMP Pathway Enhancement

Development of soluble and membrane guanylate cyclase activators and PDE5 inhibitors for cardiovascular and pulmonary vascular disease treatment.

Protein Kinase C Isozyme Selectivity and Membrane Translocation

Rational design of PKC isozyme-selective modulators achieving translocation-dependent activation with applications in cancer and neurological disease.

Rho Family GTPase Activation and Cytoskeletal Dynamics

Discovery of selective Rho, Rac, and Cdc42 modulators targeting GEF and GAP interactions to regulate cell migration and invasion.

Ras Related in Brain GTPase Effector Selectivity

Design of Rap1 and Rap2 modulators achieving selective RAF-independent or independent MAPK activation for therapeutic benefit.

Arf Family GTPase Trafficking and Vesicle Biogenesis

Characterization of ARF modulators and COPII coat assembly inhibitors to modulate intracellular trafficking in cancer and neurodegenerative disease.

Wnt Signaling Beta Catenin Independent Pathways

Discovery of compounds modulating planar cell polarity and calcium signaling downstream of Frizzled receptors independently of TCF-LEF transcription.

Hippo Pathway YAP TAZ Modulation and Transcriptional Control

Development of YAP and TAZ modulators targeting LATS kinase inhibition and TEAD interaction for organ size control and cancer therapy.

Notch Receptor Gamma Secretase Independence

Design of compounds modulating Notch signaling through gamma-secretase independent mechanisms to improve therapeutic efficacy in cancer treatment.

BMP Smad Signaling Selective Pathway Modulation

Rational design of BMP receptor modulators achieving selective ALK2, ALK3, or ALK6 activation for bone morphogenesis and metabolic applications.

Bone Morphogenetic Protein Non Smad Signaling Modulation

Discovery of compounds selective for BMP-induced p38 and ERK activation independently of SMAD pathway engagement.

Nuclear Factor Kappa B Transcriptional Complex Disruption

Development of inhibitors targeting IkB kinase and p65 RelA nuclear translocation to achieve selective NF-κB pathway inhibition.

Allosteric Modulation of Nuclear Receptor Coactivator Binding

Investigation of allosteric sites on nuclear receptors that modulate coactivator recruitment and transcriptional activity without competing at the ligand binding domain.

Bifunctional Degrader Linker Optimization and Cellular Uptake

Design and optimization of linker chemistry in heterobifunctional molecules to enhance ternary complex formation and cellular permeability for protein degradation.

Cannabinoid Receptor Pharmacology and Endocannabinoid System Modulation

Characterization of cannabinoid receptor subtypes and development of selective ligands targeting the endocannabinoid system for therapeutic applications.

Contactin Associated Protein Lipoxygenase Inhibition Mechanisms

Molecular mechanism studies of lipoxygenase inhibitors and their effects on contactin-associated proteins in neuroinflammatory disease models.

DNA Methyltransferase Inhibition and Epigenetic Reactivation

Development of selective DNMT inhibitors that reverse aberrant DNA methylation patterns and restore expression of tumor suppressor genes.

Estrogen Receptor Alpha and Beta Tissue Selective Agonism

Discovery and characterization of ligands with differential selectivity for estrogen receptor subtypes to achieve tissue-specific pharmacological outcomes.

Fibroblast Growth Factor Receptor Mutation Specific Inhibitors

Structure guided development of FGFR inhibitors that selectively target oncogenic mutations while sparing wild type kinase activity.

GABA Receptor Subunit Selective Positive Allosteric Modulation

Design of benzodiazepine site ligands and novel allosteric modulators with selectivity for specific GABA-A receptor isoforms.

Histone Deacetylase Isoform Selectivity and Mechanism of Action

Development of HDAC inhibitors with selectivity for specific isoforms to minimize off target effects and improve therapeutic windows.

Interleukin Receptor Signaling and Biased Cytokine Response

Investigation of biased signaling through interleukin receptors to selectively activate therapeutic versus pathogenic downstream pathways.

Janus Kinase Selectivity and Pseudokinase Domain Interactions

Structure activity relationship studies of JAK inhibitors targeting individual isoforms with investigation of pseudokinase domain allosteric effects.

Kinesin Motor Protein Inhibition and Microtubule Dynamics

Pharmacological modulation of kinesin family motors to regulate axonal transport and microtubule organization in neurological disease models.

Leucine Rich Repeat Kinase 2 Mutations and Parkinson Disease

Development of LRRK2 kinase inhibitors targeting pathogenic mutations and investigation of substrate selectivity in neurodegeneration.

Map Kinase Pathway Feedback Loop Inhibition and Resistance

Rational design of combination therapies targeting MAP kinase pathway feedback loops to overcome acquired resistance mechanisms.

Neurotrophin Receptor Signaling and Axonal Survival Pathways

Development of small molecule neurotrophin receptor agonists that promote axonal growth and neuronal survival in degenerative diseases.

Orphan Nuclear Receptor Agonist Discovery and Mechanism

High throughput screening and structure based design to identify and characterize ligands for orphan nuclear receptors with unknown function.

Quinone Metabolite Formation and Toxicity Prediction Models

Development of computational and biochemical assays to predict quinone metabolite formation and associated hepatotoxicity risk.

Rho GTPase Activation and Cytoskeletal Reorganization Pharmacology

Design of Rho GTPase modulators to regulate actin cytoskeleton dynamics and control cell migration and invasion phenotypes.

Sphingosine 1 Phosphate Receptor Tissue Trapping Effects

Investigation of S1P receptor modulation and functional selectivity to achieve lymphocyte sequestration without cardiotoxic effects.

Topoisomerase Poisoning and DNA Damage Selectivity

Characterization of topoisomerase inhibitors that selectively stabilize enzyme DNA complexes in cancer cells versus normal cells.

Ubiquitin Proteasome System Substrate Recognition Selectivity

Investigation of E3 ubiquitin ligase substrate selectivity and design of inhibitors that prevent proteolysis of specific protein targets.

Vascular Endothelial Growth Factor Receptor Heterodimerization

Study of VEGF receptor isoform specific dimerization patterns and selective inhibition of pathologic versus physiologic angiogenesis.

Wnt Receptor Frizzled Selectivity and Canonical Pathway Inhibition

Development of Frizzled receptor antagonists with selectivity for canonical versus non canonical Wnt signaling in developmental disease models.

X Linked Inhibitor of Apoptosis Protein Antagonists

Design of XIAP antagonists that sensitize cancer cells to apoptosis while avoiding damage to normal cell survival mechanisms.

YAP TAZ Pathway Inhibition and Organ Size Control

Discovery of small molecule inhibitors targeting the Hippo pathway effectors YAP and TAZ to control organ growth in disease states.

Zinc Finger Protein DNA Binding Domain Modulation

Development of small molecules that allosterically modulate zinc finger protein DNA binding to selectively inhibit pathogenic transcription.

Adenosine Receptor Subtype Selective Agonism and Antagonism

Design of adenosine receptor ligands with selectivity for A1, A2a, A2b, or A3 subtypes to achieve cardioprotective or immunomodulatory effects.

Bromodomain and Extra Terminal Protein Inhibition in Epigenetics

Development of BET protein inhibitors that disrupt acetylated histone recognition and suppress oncogenic transcription programs.

Complement Component 5a Receptor Antagonists Inflammation

Discovery of C5a receptor antagonists that selectively block neutrophil recruitment while preserving other complement functions.

Death Receptor Ligand Induced Apoptosis and TRAIL Sensitivity

Investigation of TRAIL receptor agonism and sensitization strategies to overcome apoptosis resistance in cancer cells.

Endothelin Receptor Antagonism in Pulmonary Hypertension

Development of selective endothelin receptor A and B antagonists for treatment of pulmonary hypertension and vascular dysfunction.

Fatty Acid Amide Hydrolase Inhibition and Endocannabinoid Elevation

Design of FAAH inhibitors that increase endocannabinoid levels to produce analgesia and anxiolysis without direct receptor activation.

Glycogen Synthase Kinase 3 Beta Inhibition and Neuroprotection

Development of GSK3 beta inhibitors that promote neuroprotection through Wnt signaling activation and tau dephosphorylation.

Heat Shock Protein 90 Chaperone Inhibition and Client Stability

Design of Hsp90 inhibitors that selectively destabilize mutant client proteins while maintaining housekeeping chaperone function.

Indoleamine 2 3 Dioxygenase Inhibition and Immunotherapy Potentiation

Development of IDO inhibitors that restore T cell tryptophan availability and enhance anti tumor immune responses.

Junctional Adhesion Molecule Antagonism and Barrier Function

Investigation of JAM protein antagonists to modulate tight junction permeability and leukocyte extravasation in inflammatory disease.

Kallikrein Kinin System Inhibition and Bradykinin Antagonism

Development of selective bradykinin B1 and B2 receptor antagonists to treat hereditary angioedema and inflammatory conditions.

Lysophosphatidic Acid Receptor Signaling in Fibrosis

Discovery of LPA receptor antagonists that block profibrotic signaling and inhibit myofibroblast activation and collagen deposition.

Mechanistic Target of Rapamycin Complex Selectivity and Immunosenescence

Design of mTORC1 and mTORC2 selective inhibitors to modulate immune aging and restore T cell proliferation capacity.

Netrin 1 Receptor Signaling and Axon Guidance Pharmacology

Development of small molecule modulators of netrin receptors to enhance axon guidance and promote neural regeneration.

Oxysterol Receptor Ligand X Activation and Lipid Homeostasis

Discovery of LXR agonists that promote reverse cholesterol transport and reduce hepatic steatosis in metabolic disease.

Phosphodiesterase Isoform Selectivity and cAMP cGMP Signaling

Design of selective phosphodiesterase inhibitors targeting individual isoforms to modulate tissue specific second messenger levels.

Programmed Death Ligand 1 and Checkpoint Blockade Enhancement

Development of PD L1 antagonists and strategies to overcome resistance to checkpoint inhibition in cold tumors.

Quercetin Analog Design and Flavonoid Bioavailability Improvement

Chemical optimization of flavonoid natural products to improve oral bioavailability and target engagement for anti inflammatory effects.

Retinoid X Receptor Selective Activation and Gene Transcription

Discovery of RXR selective agonists that achieve tissue specific transcriptional responses without activating related nuclear receptors.

Sortilin Targeting for Progranulin Lysosomal Degradation Prevention

Investigation of sortilin antagonists to prevent progranulin trafficking to lysosomes and maintain neuroprotective signaling.

T Cell Costimulatory Molecule Modulation and Proliferation Control

Design of CD28, ICOS, and OX40 pathway modulators to enhance or suppress T cell activation depending on disease context.

Unfolded Protein Response Sensor Activation and ER Stress Adaptation

Development of molecules that selectively activate ATF6, IRE1, or PERK UPR branches to resolve proteotoxic stress.

Splicing Factor Modulation in Disease Treatment

This research focuses on developing small molecule modulators that alter pre-mRNA splicing patterns to correct aberrant transcripts in genetic diseases and cancer through targeting SR proteins and splicing regulatory elements.

Vav Guanine Nucleotide Exchange Factor Inhibition in Leukocytes

Discovery of Vav GEF inhibitors that selectively suppress Rho GTPase activation in immune cells without affecting other cell types.

Ferroptosis Induction and Iron Homeostasis Pharmacology

This research investigates pharmacological approaches to selectively trigger ferroptotic cell death through iron accumulation and lipid peroxidation as a novel therapeutic strategy for cancer and neurodegenerative disease resistant to apoptosis.